AmoyDx Announces Companion Diagnostic Collaboration with Servier for Vorasidenib in IDH-Mutant Glioma

Jun 27, 2024 14:22 CST Updated 14:22

Servier

International Pharmaceutical Manufacturers

Amoy Diagnostics Co. LTD. announced that recently, the company signed a companion diagnostic cooperation agreement with LES LABORATOIRES SERVIER ("Servier"). The companion diagnostic product independently developed by the company for its next-generation sequencing (NGS) platform is used to detect isocitrate dehydrogenase (IDH) 1 and 2 gene mutations; this companion diagnostic product will be used for Servier's investigational new drug vorasidenib, a dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2), which is expected to be used for treating Chinese patients with IDH-mutant diffuse glioma (LGG) after approval.

It is reported that Servier is an international group managed by a foundation, with the mission of serving human health, and aims to bring profound social impact for patients and the sustainable development of the world. With its unique management model, Servier fully commits to its long-term mission with a forward-looking vision: advancing progress in therapeutic fields and meeting patients' needs.

The listed company stated that its circle of pharmaceutical enterprise friends continues to expand, with cooperation fields and regions constantly broadening. From TKIs targeted drugs and PARPi drugs to immunotherapy drugs and ADC drugs, the company has achieved a forward-looking layout in companion diagnostic products, seizing the innovative source of the future market. This collaboration with Servier on companion diagnostics will further enhance the company's competitiveness in the precision oncology market and have a positive impact on the company’s future development.